Related Experiment Video

Updated: Sep 3, 2025

Evaluating Cell Death Using Cell-Free Supernatant of Probiotics in Three-Dimensional Spheroid Cultures of Colorectal Cancer Cells
06:07

Evaluating Cell Death Using Cell-Free Supernatant of Probiotics in Three-Dimensional Spheroid Cultures of Colorectal Cancer Cells

Published on: June 13, 2020

6.8K

Inhibition of Colon Cancer Recurrence via Exogenous TRAIL Delivery Using Gel-like Coacervate Microdroplets

Sungjun Kim1, Yerim Jwa1, Jiyeon Hong1

  • 1Department of Chemical & Biochemical Engineering, Dongguk University, 30, Pildong-ro 1-gil, Jung-gu, Seoul 22012, Korea.

Gels (Basel, Switzerland)
|July 25, 2022
PubMed

Insights

A novel gel delivery system effectively protects tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL) and suppresses colon cancer recurrence. This platform ensures sustained drug release, preventing cancer cell re-proliferation after a single administration.

Area of Science:

  • Biomaterials Science
  • Cancer Biology
  • Drug Delivery Systems

Background:

  • Colon cancer (CC) is a major malignancy with a high recurrence rate, necessitating innovative treatments.
  • Tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL) shows promise for cancer therapy due to its specific apoptosis-inducing properties.
  • The short in vivo half-life of TRAIL poses a significant challenge for its clinical application.

Purpose of the Study:

  • To develop a novel drug delivery platform for effective colon cancer treatment.
  • To enhance the stability and prolong the therapeutic effect of TRAIL.
  • To investigate the potential of the developed system in preventing colon cancer recurrence.

Main Methods:

  • Development of a gel-like mPEGylated coacervate (mPEG-Coa) delivery platform via electrostatic interaction.
  • Encapsulation of TRAIL within the mPEG-Coa system for protection against proteases.
  • Evaluation of sustained TRAIL release over 14 days and its effect on HCT-116 colon cancer cell recurrence in vitro.

Main Results:

  • The mPEG-Coa platform successfully protected TRAIL from degradation and ensured sustained release for 14 days.
  • Treatment with TRAIL-loaded mPEG-Coa significantly suppressed HCT-116 cell recurrence compared to bolus TRAIL administration.
  • The delivery system maintained TRAIL bioactivity, enabling long-term continuous supply.

Conclusions:

  • The developed gel-like mPEG-Coa system is a functional delivery platform for TRAIL.
  • This platform demonstrates potential for suppressing colon cancer recurrence through sustained delivery of active TRAIL.
  • Single administration of TRAIL-loaded mPEG-Coa offers a promising strategy for long-term colon cancer management.
Keywords:
TRAILcancer recurrencecoacervatecolon cancerdrug delivery system

More Related Videos

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma07:59

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

6.5K
Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)08:42

Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)

Published on: June 27, 2025

468

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
229
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
259
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
310
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K